ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing
spondylitis(AS). The primary objective is to estimate the relationship between different dose
regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis
International Society 40 (ASAS40) response at Week 16 in subjects with active AS.